Please assess the completion status of the following clinical trial:

Trial Title: Nesiritide and Renal Function After the Total Artificial Heart

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Implanted with a total artificial heart (CardioWest) or Left ventricular assist device (HeartMate II)~* Age \> 18 years~Exclusion Criteria:~* Previous calcineurin inhibitor (CNI) exposure~* Hemodialysis prior to device implant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Total Artificial Heart (Type: EXPERIMENTAL): Nesiritide
- Total Artificial Heart: Placebo (Type: PLACEBO_COMPARATOR): Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo
- LVAD: Nesiritide (Type: ACTIVE_COMPARATOR): Active arm of the LVAD group
- LVAD: Placebo (Type: PLACEBO_COMPARATOR): Control arm for subjects receiving LVAD and randomized to placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).